Recent studies have suggested that progestogen-only contraceptives and combined estrogen/progestogen oral contraceptives (COCs) may increase the risk of breast cancer among women less than 35 years of age or among recent users. The authors conducted a case-control study, in which cases of breast cancer (n = 419) and controls (n = 1,625) hospitalized for conditions unrelated to contraceptive use were interviewed from 1994 to 1997 in hospitals in greater Cape Town, South Africa. The women were aged 20-54 years, resided in a defined area around Cape Town, and were Black or of mixed racial descent. The relative risk for exposure to injectable progestogen contraceptives (IPCs), mostly depot medroxyprogesterone acetate, was 0.9 (95% confidence interval (Cl) 0.7, 1.2). There were no consistent associations within categories of age or recency or duration of use. For exposure to COCs, the overall relative risk was 1.2 (95% Cl 1.0, 1.5). Among women below age 35 years, the relative risk was 1.7 (95% Cl 1.0, 3.0), and it was unrelated to the duration or recency of use. The findings suggest that IPCs do not increase the risk of breast cancer, and that COCs may increase the risk among women below age 35 years, although bias cannot be excluded. Am J Epidemiol 2000^ 51:396-403. 
beagle bitches (4) , and for that reason it was not licensed in the United States for use as a contraceptive until 1992 (5), after two epidemiologic studies independently reported no evidence of an overall increase in the risk of breast cancer among exposed women (6, 7) . However, the studies raised the suspicion that DMPA may increase the risk among women below age 35 years, or, alternatively, among currently exposed women, and for a few years after they stop.
In contrast to DMPA, combined estrogen/progestogen oral contraceptives (COCs) have been subjected to repeated epidemiologic assessment of breast cancer risk from the time they were introduced (8) (9) (10) (11) (12) . The evidence in early studies was generally reassuring. In recent years, however, associations have been observed, again in relation to the occurrence of breast cancer before age 35 years or among currently or recently exposed women. In a collaborative reanalysis of data from 54 studies (13, 14) , the risk was highest among current COC users, with a decline to baseline some 10 years after cessation of use. For the most part, the associations have been of modest size, and it has not been clear whether they were causal or due to bias (8) (9) (10) (11) (12) (13) (14) .
In South Africa, DMPA has been used more commonly, and for longer durations, than anywhere else in the world (15) , and recently another injectable progestogen, norethisterone enanthate, has also been used. The high usage rates of IPCs afforded an oppor-tunity to evaluate breast cancer risk overall and within subgroups. COC use has also been quite common (15) . In this report, we evaluate the risk of breast cancer among women exposed to IPCs and COCs.
MATERIALS AND METHODS

Study base
A case-control study was conducted in a base population that comprised all Black and Colored women (women of mixed racial descent) who lived within a defined area surrounding Cape Town, and who were 20-54 years of age. White women were not included because family planning clinic records indicated that IPC use was uncommon. In 1991 (16) , the study population comprised 540,121 women (Colored, 414,042; Black, 126,079).
Cases
The cases were women with first occurrences of invasive breast cancer treated between January 1994 and October 1997 at two tertiary care hospitals in Cape Town. Women with carcinoma-in-situ, those who had a previous history of cancer, or those who had not resided in the study region for at least 6 months out of the preceding 12 months, were excluded. There were 490 eligible cases, of whom three were too ill to be interviewed, and three refused. Among the remaining 484 cases, the median age was 44 years; 419 cases (87 percent) were Colored and 65 (13 percent) were Black.
Until 1996, virtually all cases in the study region were seen at the two hospitals because these were the sole institutions that provided specialized care, including radiotherapy and chemotherapy. Thereafter, such services also became available elsewhere, and were accessible to women with comprehensive medical insurance (membership in a medical aid society). Based on 249 cases identified in 1994 and 1995, the estimated annual incidence of breast cancer was 23.1 (Colored, 25.6; Black, 14.7) per 100,000. Among women aged 20-34, 35-44, and 45-54 years, the rates were 6.2, 37.1, and 69.5 per 100,000, respectively.
Controls
The controls were women admitted for diagnoses judged to be independent of contraceptive use and breast cancer risk: women admitted for conditions such as venous thromboembolism, ischemic heart disease, or benign breast disease were not eligible. The controls were frequency-matched to the cases in a ratio of up to 4:1 for decade of age, ethnic group, and area of residence. For cases referred from outlying hospitals, controls referred from the same areas were enrolled, or failing that, they were recruited in hospitals located in those areas (196 subjects; 12 percent of the total). As with the cases, women with a history of cancer, and those who had not been resident in the study region for at least 6 months out of the preceding 12 months were excluded. There were 1,627 eligible controls, two of whom refused to participate. Among the remaining 1,625 controls, the median age was 41 years; 1,402 (86 percent) were Colored, and 223 (14 percent) were Black.
Data collection
A questionnaire written in English, Afrikaans, or Xhosa was administered in the subjects' preferred language by qualified nurses. To maximize recall, the interviewers compiled a calendar of significant personal events (age at menarche, births, etc.), and periods of contraceptive use were related to those events. COC packages were shown to the women to facilitate identification. DMPA and norethisterone are administered at 3-and 2-month intervals, respectively. Thus, when the women could not remember the name of the IPC, it could be identified either as DMPA or norethisterone from the reported time interval between injections.
Data analysis
Information on a wide range of variables was recorded in order to control confounding, and relative risks (odds ratios) were estimated using unconditional multiple logistic regression. Family history of breast cancer, history of benign breast disease, late age at first birth, and low parity or nulliparity were associated with breast cancer, but not with IPC or COC use. Breast feeding was not related to breast cancer risk. These factors were nevertheless included in initial multivariate models, but they had no effect on the relative risk estimates for contraceptive exposure; adjustment for urban or rural area of residence also had no effect. High socioeconomic status was strongly associated with breast cancer, and this factor was also related to contraceptive use. Of the indices used to measure socioeconomic status (years of education, employment status, medical insurance coverage), the one that most strongly differentiated between the cases and the controls was medical insurance coverage: no insurance, membership in a sick fund (limited insurance), and membership in a medical aid society (comprehensive insurance) were used to denote low, intermediate, and high status, respectively. The final regression models included terms for IPC and COC use, age, ethnic group, and socioeconomic status, as indicated by insurance coverage. 
RESULTS
Among the 1,625 controls (table 1) 71 percent had used IPCs, and 27 percent were exposed for >5 years. For COCs, the corresponding rates were 39 and 8 percent. There was little variability according to diagnosis.
Injectable progestogen contraceptives
Among the 484 cases and 1,625 controls, 318 (66 percent) and 1,161 (71 percent), respectively, had used IPCs (relative risk (RR) = 0.9, 95 percent confidence interval (CI) 0.7, 1.2) (table 2). For total durations of use that extended from <1 year to >10 years, the overall relative risk estimates ranged from 0.8 to 1.0. For intervals since first use that extended from <5 years to >15 years, the overall estimates ranged from 0.8 to 1.2. For intervals since last use that extended from 1-4 to >15 years, the overall relative risk estimates were 1.1 or less. The 95 percent confidence intervals for all of the foregoing estimates included 1.0. The relative risk was 1.6 (95 percent CI 1.1, 2.3) among current IPC users (women last exposed less than a year previously). However, of the 59 cases and 248 controls last exposed 1-4 years previously (table 2), 28 and 120, respectively, had last received IPCs in the previous 1-2 years, and the relative risk estimate was 1.1. Among current IPC users the relative risk estimate of 1.6 did not vary significantly according to duration of use (data not shown).
In the age-specific data (table 2) , among women who were aged 35^44 years, the relative risk for current IPC use was 2.3 (95 percent CI 1.3, 4.1); among women aged <35 years and 45-54 years, the corresponding estimates were 1.2 and 1.4, respectively, and compatible with unity. In the remaining categories of duration, and of intervals since first and last exposure, there were no significant associations, and the relative risk estimates ranged from 0.5 to 1.8.
There were 419 and 1,402 Colored cases and controls, of whom 261 (62 percent) and 982 (70 percent), respectively, had used IPCs (RR = 0.9, 95 percent CI 0.7, 1.1). Among 65 and 223 Black women, the corresponding numbers were 57 (88 percent) and 179 (80 percent) (RR = 2.0, 95 percent CI 0.8, 4.9). DMPA was used by 277 cases and 1,001 controls (RR = 0.9, 95 percent CI 0.7, 1.2); norethisterone was used by 13 cases and 64 controls (RR = 0.7, 95 percent CI 0.3, 1.5).
To assess the possibility that COC use may have modified the effects of IPCs, the analysis was repeated after excluding 220 cases and 633 controls exposed to COCs. Among the remaining 264 cases and 992 controls, 161 and 663, respectively, had used IPCs (RR = 1.1, 95 percent CI 0.8, 1.5). One study has reported an elevated risk lasting up to 4 years after a single injection of DMPA (6): in the present study, one case and seven controls had received a single injection (in all instances DMPA) less than 5 years previously (crude RR = 0.7). It has also been hypothesized that hormonal exposure during adolescence or early adulthood may increase the risk (17): there were 44 cases and 227 controls who were aged 18 years or younger when they were first exposed to IPCs (RR = 0.8, 95 percent CI 0.5, 1.2).
Selection bias could have occurred if contraceptive usage patterns differed between the cases enrolled in this study, and those who were not enrolled because they attended private clinics. There were 409 cases and 1,538 controls who were not members of medical aid societies (and who could not attend private clinics), of whom 277 and 1,097, respectively, were exposed to IPCs (RR = 1.0, 95 percent CI 0.8, 1.3). Bias could also have occurred if otherwise occult breast cancer was selectively diagnosed among IPC users (detection bias) (18) . There were 292 cases and 1,010 controls who had never previously undergone a breast examination, self-examination, or mammography: among 
Combined estrogen/progestogen oral contraceptives
Among the 484 cases and 1,625 controls 220 (45 percent) and 633 (39 percent), respectively, had used COCs (RR = 1.2, 95 percent CI 1.0, 1.5) (table 3). For total durations of use that extended from <1 year to >10 years, the overall relative risk estimates ranged from 1.1 to 1.4, and there was no evidence of a trend. For intervals since first exposure that extended up to 15 or more years, the overall estimates ranged from 1.1 to 1.7, and all 95 percent confidence intervals included unity. For current COC use, the relative risk was 1.1 (95 percent CI 0.6, 2.1), and for last exposure \-A years previously, it was 1.6 (95 percent CI 1.1, 2.3); for intervals since last exposure of 5-9, 10-14 and >15 years, the estimates were 1.3, 1.4, and 0.9, respectively, and compatible with unity.
Among 70 cases and 394 controls below age 35 years (table 3), the overall relative risk estimate for COC users was 1.7 (95 percent CI 1.0, 3.0). For total durations of exposure of <1, 1-4, and 5-9 years the relative risks were 2.1, 2.0, and 2.0, respectively; the former two estimates were statistically significant. For COC use that had commenced <5, 5-9, and 10-14 years previously, the relative risk estimates were 1.8, 2.5 (significant), and 1.9. For current COC use, and for last exposure 1-4, 5-9, and 10-14 years previously, the relative risk estimates were 1.6, 2.2 (significant), 1.7, and 3.0 (significant), respectively.
Among women in age groups 35-44 and 45-54 years (table 3), the overall relative risk estimates were 1.2 and 1.1, respectively, and compatible with unity. There were no significant associations according to duration of use, or according to the interval since first or last use, and no evidence of a declining risk as the interval since last exposure increased.
Among 419 and 1,402 Colored cases and controls, 189 and 560, respectively, had used COCs (RR =1.1, 95 percent CI 0.9, 1.4). Among 65 and 223 Black cases and controls, the corresponding numbers were 31 and 73 (RR = 1.7, 95 percent CI 1.0, 3.1). Among 166 cases and 464 controls who were never exposed to IPCs, 63 and 135, respectively, had used COCs (RR = 1.4, 95 percent CI 0.9, 2.0). First exposure to COCs before age 19 years was reported by 13 cases and 69 controls (RR = 0.8, 95 percent CI 0.4, 1.4).
Among 409 cases and 1,538 controls who were not members of medical aid societies, 170 and 583, respectively, had used COCs (RR = 1.1, 95 percent CI 0.9, 1.4). Among 292 cases and 1,010 controls who had never had a breast examination or mammogram, 111 and 355, respectively, had used COCs (RR = 1.0, 95 percent CI 0.8, 1.4). For women with stages 1-4 breast cancer, the relative risk estimates (95 percent CIs) were 1.7 (1.2, 2.4), 1.5 (1.0, 2.2) , 0.8, and 1.0, respectively.
DISCUSSION
The present findings suggest that IPCs, principally DMPA, do not increase the overall risk of breast cancer: the relative risk was 0.9, and a value of more than 1.2 could be ruled out with 95 percent confidence. Nor was there evidence to suggest that the risk increased with prolonged duration of use. In the overall data, the only statistically significant relative risk was an estimate of 1.6 for current IPC use. However, in the immediately contiguous category of women who had stopped using IPCs 1-2 years previously, the estimate was 1.1. In addition, the association with current exposure was inconsistent according to age, and it was mainly accounted for by a relative risk estimate of 2.3 among women aged 35^44 years.
There was also no evidence to suggest that IPCs cause a transitory increase in the risk during a period lasting 4-5 years after exposure has been discontinued, or that their use is associated with the occurrence of breast cancer at a young age, or that IPCs increase the risk after prolonged time lapses, extending to more than two decades. Nor was there evidence to suggest that women who were exposed during adolescence or early adulthood, when the breast was growing rapidly (17) , were at increased risk.
For women exposed to COCs, there was an overall 1.2-fold increase in the risk that was of borderline statistical significance. The risk did not vary significantly according to duration of use, or according to the interval since first or last use. In particular, there was no evidence to suggest that the risk was highest among currently exposed women, followed by a decline as the interval after stopping the use of COCs extended for a decade or longer (13, 14) . The overall relative risk of 1.2 was mainly accounted for by an estimate of 1.7 among women less than 35 years of age. In that age group, the risks were uniformly elevated for all durations of use. They were also elevated for intervals since first or last use that extended up to 15 years. Again, there was no evidence to suggest an initial increase in the risk among currently exposed women, followed by a decline, as the interval after stopping COC use increased. Among women in the age groups 35-44 and 45-54 years, all relative risk estimates were compatible with unity.
It is important to consider whether bias could have accounted for any of the associations identified in this study. Information bias could have occurred if the cases reported their contraceptive exposures more fully than the controls. For COC users, it is possible that greater awareness of the hypothesis among women below age 35 years may have contributed to the observed association.
The selection of the cases could have been biased if breast cancer tended to be diagnosed more commonly, or earlier, among exposed than among nonexposed women (18) . Evidence to support that possibility was the decline in the relative risk for COC use, from a statistically significant value of 1.7 among women with stage 1 to 1.0 among women with stage 4 breast cancer. Other sources of biased case selection are unlikely because until 1996 virtually all cases in the study base were enrolled, and the findings were unchanged when the analysis was confined to women who did not have access to private clinics. It is unlikely that selection bias affected the controls: women were only included if their reason for hospitalization was independent of contraceptive use, and of breast cancer risk, and the enrollment of eligible subjects was virtually 100 percent. The similar usage rates of IPCs and COCs in the major diagnostic categories that comprised the control series is additional evidence against bias.
Potential confounding was controlled, partly by series-matching, and more fully by multivariate adjustment. In addition, as can readily be calculated, all crude relative risk estimates approximated the corresponding estimates derived by multiple logistic regression, suggesting that there was no material confounding.
Earlier studies of contraceptives that contain progestogens, but no estrogens, have in general suggested that these agents do not increase the overall risk of breast cancer (6, 7, 20) . However, they have been discordant with regard to effects within subgroups. In a case-control study confined to British women below age 35 years (21) , there was a reduced risk of breast cancer among women who used oral progestogen-only contraceptives for >8 years. By contrast, two casecontrol studies of DMPA users, one from New Zealand (6) and the other conducted in several countries by the World Health Organization (WHO) (7) were null overall, but each identified increased risks among women who were less than 35 years of age, and among women who had been exposed <5 years previously. Exposure at a young age and recent exposure were highly correlated, and in an attempt to distinguish between their separate effects, the investigators pooled the data from the two studies (22) . They concluded that the probable key factor was an increased risk during the 5-year period following exposure to DMPA, regardless of age, rather than an elevated risk confined to young women. In 1996, the New Zealand data were again analyzed, this time to assess the effects of oral progestogen contraceptives (23) . There was no overall increase in breast cancer risk, but increased risks were observed among women below age 35 years, and among those exposed <10 years previously. Among those exposed >10 years previously, the risk was significantly reduced.
Based on the New Zealand (6) and WHO (7) studies of DMPA, and on the New Zealand findings for oral progestogen contraceptives (23) , it has been suggested that exposure to progestogen contraceptives may mimic pregnancy, and have analogous effects on the general pattern of breast cancer risk (24) . That is, as has been postulated for pregnancy, exposure to progestogens may initially increase the risk for a few years, followed by a decline to an eventual longlasting reduction in the risk. Thus, because breast cancer becomes more common with advancing age, the net effect may be to reduce the lifetime risk. The present findings do not support that suggested pattern of events. In addition, the postulated effect of pregnancy itself on breast cancer risk was not evident in the New Zealand data (23) , and it is controversial (24) .
For COC use, the present findings are discordant with those reported in a pooled reanalysis of 53,297 cases and 100,239 controls from 54 studies (13, 14) , in which the relative risk estimates for current users, and those who stopped using COCs 1-4, 5-9, and >10 years previously were 1.24, 1.16, 1.07 and 1.01, respectively-a pattern that was evident in all age groups. In the present study, there was no evidence of a corresponding pattern of initial risk elevation, followed by a decline. Moreover, the positive association with COC use observed in this study was largely confined to the youngest women, among whom the relative risk estimates were in the range of 1.6-3.0 in all categories of recency of use extending up to 15 years previously. In some of the studies included in the pooled analysis, the association was strongest at the youngest ages (8, 10, 25, 26) , in accord with the present findings. It is also possible that there may have been shared biases among the included studies that could have accounted for the small risk increments that were observed. In addition, the positive associations were largely confined to early-stage breast cancer, as in the present study. The investigators were unable to conclude whether the findings reflected cause and effect, or bias.
It remains to consider the public health implications of the present findings. For women who use IPCs, DMPA in particular, there was no evidence of an overall increase in the risk of breast cancer, and for currently exposed women, the relative risk was 1.6. With regard to COCs, the overall relative risk was 1.2, and it was 1.7 among women below age 35 years. These associations could have been due to chance or bias. If causation is assumed, however, based on an annual incidence of breast cancer of 23 per 100,000 among women who are 20-54 years of age, the estimated excess risk (27, 28) attributable to current IPC use is 13 per 100,000; for any COC use, it is 4 per 100,000. Among women below age 35 years, based on an annual incidence of 6 per 100,000, the excess risk attributable to any COC use is 3 per 100,000. Thus, even under the most adverse assumptions, the incidence rates of breast cancer among IPC and COC users that can be attributed to exposure are small.
